118 Fatal Varicella-zoster virus infections in immunocompromised children: Limitation of current guideline to prevent nosocomial infection  by Moriuchi, H. et al.
S66 International Journal o[ In[ectious Diseases (2006) 10(S1 ) Abstracts 
investigator-blinded safety and to[erabi[ity analysis 
when 25% of pts were included. 
Results: As of March 2006, 128 pts were included. 
Complete safety data of 120 pts are available. 
61 of 120 pts had a double lumen CVC, 58 of 120 
pts received ethanol Pts received a mean of 
29.5 locks. Incidence of side effects and laboratory 
abnormalities are given in table 1. g-GF, ASAT and 
MCV on dO as we[[ as after 14 days of locking 
with ethanol vs placebo were comparable between 
groups (p >0.5 for a[[). Overall to[erabi[ity of the 
ethanol locks was good (table 1) but some patients 
had side effects during or immediately after locks 
were flushed through the 2 or 3 [umina. After in- 
clusion of 80 pts this led to an amendment that al- 
lowed pts with side effects to continue on a one lu- 
men only/day regimen. 7 of 128 pts withdrew from 
the study for side effects and after the amendment 
another 3 switched to the one lumen/day regimen 
(stop or switch: 9/64 with ethanol versus 1/64 with 
placebo, p=0.01). 7 of 32 ethanol-lock pts who 
had a triple-lumen CVC stopped or switched to a 
one lumen/day regimen versus 2 of 32 ethanol-lock 
pts with a double-lumen CVC (p=0.1). Serious or 
life-threatening adverse events were not observed. 
Tab[e 1. Incidence of side effects and [aboratory abnorma[ities 
during ethano[ [ock and p[acebo. 
P[acebo Ethano[ 70% p-va[ue 
(n=40 a) (n=49 a 
Nausea/vomiting 9 of 40 I0 of 49 
Changed taste 7 of 40 15 of 49 
Dizziness 5 of 40 6 of 49 
Facia[ flushing 10 of 40 25 of 49 
Drowsiness 5 of 40 13 of 49 
Any side e[[ect 20 of 40 30 of 49 
ASAT (IU) dO: 32, d14:26 dO: 30, d14:28 
gamma-GT (IU) dO: 63, d14:77 dO: 66, d14:87 
MCV of RBC dO: 91, d14:89 dO: 93, d14:89 
)>0.2 
)>0.2 
)>0.2 
)=0.02 
)=0.12 
)>0.2 
) >0.5 b 
)>0.5 b 
)>0.5 b 
aFar the ana[ysis of ASAT, gIGT and MCV data of 120 patients 
were avai[ab[e. The questionary on side effects was returned 
by 89 patients. 
bFor comparisons of dO and d14 data. 
Conclusion: Overall, the administration of a daily 
70%-ethanol catheter-lock was safe and we[[ toler- 
ated and no serious adverse events were observed. 
More pts are needed to prove that the locking 
of only one lumen/day is preferred in pts with a 
triple-lumen CVC. 
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Background: Since varice[[a-zoster virus is very 
contagious and causes serious diseases in the im- 
munocompromised host, prevention of nosocomia[ 
transmission is mandatory. 
Objective: To assess the efficacy of (1) the current 
guideline to prevent nosocomia[ varice[[a-zoster 
virus (VZV) infection and (2) post-exposure mon- 
itoring to promptly discover and treat secondary 
cases. 
Methods: Desisn: A 3.5-year prospective study of 
a[[ nosocomia[ VZV cases with weekly monitoring 
of viremia by real-time PCR. Settins: A 50-bed 
pediatric ward in a University Hospital Patients: 
Approximately 20-30% and 70-80% of beds occu- 
pied by patients with acute illnesses and more 
or less immunocompromised patients with chronic 
illnesses, respectively. Intervention: Among those 
susceptible to VZV or immunocompromised, a[[ in- 
patients on the ward or those who shared the room 
or had contact with the index case received inter- 
vention in case of varice[[a or zoster, respectively. 
Intervention included vaccination for immunocom- 
petent hosts, intravenous immunog[obu[in of high- 
titer neutralizing anti-VZV antibody (VZ-IVIG) for 
immunocompromised hosts within 72h, or 7-day 
course of oral acydovir from the 8th days after 
possible exposure. A[[ patients who received any 
preventive intervention were monitored weekly for 
VZV viremia for 4 weeks. 
Results: We experienced 3 index cases of varice[[a 
and 2 index cases of zoster, followed by 3 secondary 
cases, two of whom died. One survived case re- 
ceived VZ-IVIG, one fatal case received acydovir 
prophylaxis, and the other fatal case did not re- 
ceive any preventive intervention since she was 
believed to have had no direct contact with the 
index case (zoster). In two of the three cases, 
viremia was not detected 4-7 days before onset. 
Conclusions: The current guideline had limited ef- 
ficacy for prevention. Postulated secondary viremia 
may be shorter than expected in the immunocom- 
promised. 
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